Bravias Capital Group LLC Acquires New Position in iShares Biotechnology ETF (NASDAQ:IBB)

Bravias Capital Group LLC acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,734 shares of the financial services provider’s stock, valued at approximately $240,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Transcend Capital Advisors LLC raised its position in iShares Biotechnology ETF by 0.8% during the 4th quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock worth $1,449,000 after buying an additional 92 shares during the last quarter. Chicago Partners Investment Group LLC increased its holdings in shares of iShares Biotechnology ETF by 2.5% during the 4th quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock valued at $510,000 after purchasing an additional 94 shares in the last quarter. WealthCare Investment Partners LLC grew its stake in iShares Biotechnology ETF by 0.9% in the 4th quarter. WealthCare Investment Partners LLC now owns 10,348 shares of the financial services provider’s stock valued at $1,375,000 after acquiring an additional 96 shares during the period. Capital Investment Advisors LLC grew its stake in iShares Biotechnology ETF by 1.0% in the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock valued at $1,381,000 after acquiring an additional 99 shares during the period. Finally, Canton Hathaway LLC grew its stake in iShares Biotechnology ETF by 1.0% in the 4th quarter. Canton Hathaway LLC now owns 9,961 shares of the financial services provider’s stock valued at $1,317,000 after acquiring an additional 100 shares during the period. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock opened at $137.03 on Monday. The company’s fifty day moving average price is $135.91 and its 200 day moving average price is $140.61. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The stock has a market capitalization of $6.47 billion, a P/E ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.